UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Biomed Realty Trust After 4Q12 Review

In a report published Friday, Jefferies reiterated its Buy rating on Biomed Realty Trust

, and slightly raised its price target from $23.00 to $24.00. Jefferies noted, “BMR continues to benefit from a healthy life science environment, with a strong pace of FDA drug approvals and strong capital flows into the industry. As a result, the company has seen strong earnings growth driven by strong leasing and tenant demand. Significant growth opportunities remain through acquisitions, developments, and continued lease-up. Maintain Buy.” Biomed Realty Trust closed on Thursday at $20.79.